Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B - Top-Institutions - MDSpire

Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B

  • By

  • Xinrong Zhang

  • Vy H Nguyen

  • Leslie Yeeman Kam

  • Scott D Barnett

  • Linda Henry

  • Ramsey Cheung

  • Mindie H Nguyen

  • December 12, 2024

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

    Bethesda, MD

    Key Differentiators

    • Hepatology
    • Metabolic Disease
    • Epidemiology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Hepatology
    • Infectious Diseases
    • Cardiometabolic Research

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hepatology
    • Metabolic Syndrome
    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hepatology
    • Nephrology
    • Cardiology

  • #5

    Massachusetts General Hospital (MGH), Harvard Medical School
    Massachusetts General Hospital (MGH), Harvard Medical School

    Boston, MA

    Key Differentiators

    • Hepatology
    • Endocrinology
    • Epidemiology

Original Source(s)

Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B

  • by Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen

  • December 12, 2024

Related Content

Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial

Influenza Vaccine Dose and Dementia Outcomes

US claims data compare high- vs standard-dose formulations in patients aged 65 years or more over 3 years of follow-up

AI Outperforms MDs on Reasoning Tasks

Across six experiments—including a blinded, real-world ER evaluation—an OpenAI large language model outperformed physician baselines on multiple clinical reasoning tasks, though not on key safety endpoints such as cannot-miss diagnoses